An abundance of events are afoot around the world to mark Rare Disease Day 2020 on Feb. 29. The activities are focused on heightening awareness about rare diseases and the hundreds of millions of individuals they are thought to affect. Patients, caregivers, and advocates worldwide will sport denim ribbons…
News
Autoimmune hemolytic anemia (AIHA) experts gathered in Vienna, Austria, in November 2017 for the First International Consensus Meeting with the goal of summarizing current research into diagnosis and treatment of the rare genetic disorders. Now, after three subsequent meetings at medical conferences, the researchers and physicians have published their conclusions and…
The U.S. Food and Drug Administration (FDA), a vast government bureaucracy, employs about 17,500 people and had a budget of $5.7 billion in 2019. Yet even with its enormous resources, the FDA these days relies more and more on patients to…
The gleaming new Dutch headquarters of the European Medicines Agency (EMA), fronting Domenico Scarlattilaan in Amsterdam’s suburban Zuidas business district, finally opened for business last month — just over two years after the European Union decided to relocate the EMA to the Netherlands in the wake of Brexit.
Physicians have described the rare case of a woman with cold agglutinin disease (CAD) associated with advanced breast cancer. Her case was described in a case report study, “Cold autoimmune hemolytic anemia: a rare association with triple-positive breast cancer,” published in the Journal of…
The wrong blood type may be given to people with undiagnosed autoimmune hemolytic anemia (AIHA), which can lead to them receiving blood transfusions from mismatched blood donors, a case report shows. This research highlights the need for rigorous lab work to determine and confirm blood type before blood…
Autoimmune hemolytic anemia (AIHA) can be a cause for anemia in people with chronic myeloid leukemia (CML), a case report found. The study “Autoimmune Hemolytic Anemia After Relapse of Chronic Myeloid Leukemia: A Case Report” was published in the journal Clinical Medicine Insights: Blood Disorders. AIHA, an autoimmune…
Treatment with blood transfusions is safe and efficient for treating hospitalized autoimmune hemolytic anemia (AIHA) patients, a large observational study suggests. This conclusion held true even when using incompatible donors and even for the one-third of patients who developed severe anemia during hospitalization, according to the study.
T follicular helper cells, a subset of T-cells that help other immune cells produce antibodies, seem to play a role in the development of autoimmune hemolytic anemia (AIHA), a mouse study suggests. The study, “The Role of T Follicular Helper Cells and T Follicular Regulatory Cells in…
Nearly $200,000 Awarded to Cold Agglutinin Disease Foundation, Other Rare Disease Organizations
The Cold Agglutinin Disease Foundation is among 20 rare disease organizations receiving funding under Global Genes‘ 2020 RARE Patient Impact Grant Program. Now in its fifth year, the 2020 grant program is awarding funds totaling almost $200,000 to these organizations. The program provides funding for rare disease patient…
Recent Posts
- Being vigilant during transfusions brings a vital victory for this CAD patient
- Rituximab helps treat CAD linked to long-term immunosuppression: Case
- With my health from CAD steadily declining, I call in the cavalry, part 3
- Rituximab effective in rare dual autoimmune blood disorder case
- Unexplained anemia in seniors may signal autoimmune disease CAD
- With my health from CAD steadily declining, I call in the cavalry, part 2
- FDA fast-tracks potential new option for autoimmune blood diseases
- Long-term Enjaymo use shows favorable outcomes in CAD: Study
- With my health from CAD steadily declining, I call in the cavalry, part 1
- Genetic variations in underlying lymphoma influence AIHA types